category:news
Insurers continue to embrace Virtual Healthcare for GLP1s
Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
category:news
Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.
categeory:watercooler
Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.
categeory:watercooler
Ozempic face isn't real -- fast weight loss causes changes to the skin, and your face is a prime area that will change.
drug:am-133
Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.
company:eli-lilly
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.
Scientists managed to increase the number of insulin-producing cells in a human-cell-in-mouse experiment.
category:side-effects
Do GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, Zepbound, and others) cause thyroid issues?
includes:study
Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.
category:news
23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.
includes:review
Want to get refreshed on GLP1 research into drugs like Ozempic, Wegovy, Mounjaro, Zepbound and others? Start here.
drug:amycretin
Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.
category:news
What effects does GLP1 have on ADHD? It's early, but we take a look at some published research.